Oct. 17 at 3:50 PM
$APRE announced the recommended Phase 2 dose of 1,100 mg once daily for ATRN-119 in its ongoing ABOYA-119 study for advanced solid tumors. The company is pausing further monotherapy enrollment to focus on combination therapies, leveraging ATRN-119’s potential synergistic effects with DNA-damaging agents. This strategic shift aims to enhance the therapeutic potential of ATRN-119, with ongoing discussions for combination studies in HPV+ head and neck cancer and other indications.
The most recent analyst rating on (APRE) stock is a Buy with a
$10.00 price target.
https://www.msn.com/en-us/health/other/aprea-therapeutics-shifts-focus-to-combination-therapies/ar-AA1Ox205